PBRM1 as a biomarker for kidney cancer

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Centre in Texas, USA, talks about the use of PBRM1 as a potential biomarker for immune response to checkpoint inhibitors. The data for this biomarker is controversial and complicated and in the future researchers need to better understand how this relates to treatment response.

Current large phase II/III studies are rich with genomic data, and that is going to allow researchers to further clarify what the relationship is between the genomic features of the tumour, immunology, and response to therapy.

Watch the video interview on Practice Update here

Share this Post!


Related post

  TOP